Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Characteristics of JIA
To be considered JIA, onset must occur before 16 years of age.
JIA is heterogeneous: the presentation of the disease and its natural history vary among individuals and over time.
The disease is typically classified into categories based on the symptoms displayed and their severity:
- Systemic arthritis
- Rheumatoid-factor positive (RF+) polyarthritis
- Rheumatoid-factor negative (RF-) polyarthritis
- Enthesitis-related arthritis (inflammation of tendons and ligaments at the site of connection to bone)
- Psoriatic arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic
- Goldmuntz EA, White PH. Juvenile idiopathic arthritis: a review for the pediatrician. Pediatr Rev 2005;27(4):e24-25. PMID: 16581950.
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.